Cambridge, UK and Boca Raton, FL – January 2026 – Qkine Limited, a leading innovator in the development of high-quality growth factors and cytokines, and Akron Bio, a leading supplier of critical materials and services to the cell and gene therapy industry, today announced a strategic partnership focused on the joint development and global supply of ancillary materials to enable the development of stem cell-based therapeutics.
This collaboration combines Qkine’s proprietary growth factor and cytokine technologies with Akron’s established GMP manufacturing capabilities and long-standing focus on providing solutions to cell and gene therapy developers. Together, the companies will accelerate the development and delivery of innovative, high-performance recombinant proteins essential for stem cell expansion, differentiation, and maturation, addressing the need for reliable, consistent, and scalable solutions in the rapidly evolving field of regenerative medicine.
Dr. Robert Scoffin, CEO of Qkine Limited, commented: “We are delighted to partner with Akron Bio, whose reputation in GMP manufacturing and global reach complements our commitment to scientific excellence and innovation. Together, we will enable our customers to develop and manufacture advanced stem cell therapies using the highest quality reagents, with the assurance of regulatory compliance and supply chain security.”
Akron Bio’s Chief Operating Officer, Ezequiel Zylberberg, added: “Our partnership with Qkine strengthens our ability to provide comprehensive solutions across the cell therapy workflow that enable the development of novel therapeutic modalities. We are thrilled to partner with the team at Qkine, leveraging their world-class protein development capabilities to launch differentiated products that enable the industrialization of cell therapy manufacturing.”
Through this partnership, Qkine’s hematopoietic growth factors and cytokines critical for the manufacture of stem cell-based therapeutics will be made available globally and exclusively through Akron’s commercial channels, thereby providing security of supply to innovators. Moreover, the two companies will partner to develop next-generation products aimed at supporting the automated production of cell therapies, thereby enabling greater access to these life-saving treatments.
About Qkine Limited
Qkine Limited is dedicated to advancing stem cell and regenerative medicine research by developing high-purity, bioactive growth factors and cytokines. With a focus on scientific rigour and product excellence, Qkine supports cutting-edge biological research and clinical translation worldwide.
About Akron Bio
Akron Bio partners with advanced therapy innovators, delivering GMP-compliant materials and services with the scale, compliance, and regulatory expertise needed to bring novel treatments from discovery to commercialization and improve outcomes for patients with unmet needs.
For further information, please contact:
Qkine Limited Press Office: info@qkine.com
Akron Bio Media Relations: brichardson@akronbiotech.com